Hematological Safety of Metamizole: Retrospective Analysis of WHO and Swiss Spontaneous

Hematological Safety of Metamizole: Retrospective Analysis of WHO and Swiss Spontaneous Safety Reports

Lea S Blaser1, Alexandra Tramonti1, Pascal Egger2, Manuel Haschke1, Stephan Krähenbühl1, Alexandra E Rätz Bravo1,3

1Division of Clinical Pharmacology & Toxicology, University Hospital, Basel, Switzerland

2Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

3Regional Pharmacovigilance Center, University Hospital, Basel, Switzerland

Corresponding author

Stephan Krähenbühl, MD, PhD

Clinical Pharmacology & Toxicology

University Hospital

Hebelstrasse 2

CH-4031 Basel

Phone: ++41 61 265 47 15

Fax: ++ 41 265 45 60

E-mail:

Supplementary Table 1.

Age categories retrieved from international and the subgroup of Swiss individual case safety reports of metamizole-associated hematological adverse drug reactions between 1968-01/2013 and 1991-2012, respectively

Supplementary Table 2.

Drug classes of co-suspected drugs retrieved from the subgroup of Swiss individual case safety reports of metamizole-associated hematological adverse drug reactions between 1991-2012

Supplementary Table 3.

Most prevalent underlying diseases expressed as ICD-10 codes among 65 Swiss metamizole-associated hematological individual case safety reports (ICSR) reported to Swissmedic between 1991-2012

Supplementary Table 4.

Detailed information on the seven Swiss individual case safety reports of metamizole-associated hematologic adverse drug reactions between 1991 and 2012 with fatal outcome